Live Breaking News & Updates on Pliant Therapeutics Company Profile

HC Wainwright restated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $54.00 target price on the stock. Several other analysts have also issued reports on PLRX. Royal Bank of Canada dropped their target price on […] ....

United States , Bernard Coulie , Eric Lefebvre , Jpmorgan Chase Co , Dimensional Fund Advisors , Cantor Fitzgerald , Royal Bank , Pliant Therapeutics Inc , Salem Investment Counselors Inc , Topco Ltd , Acadian Asset Management , Pliant Therapeutics Company Profile , Needham Company , Pliant Therapeutics , Get Rating , Asset Management , Investment Counselors , Pliant Therapeutics Daily , Nasdaq Plrx , Reiterated Rating , Hc Wainwright ,